Join our Provider Relations team members for the virtual provider collaboration session(s). Register Now
Processing...
Please wait while your form is being submitted
Register for the upcoming 2027 Change Provider Trainings
Join our Provider Relations team members for the virtual provider collaboration session(s). Register Now
Beginning Jan. 1, 2026, Lisdexamfetamine (generic Vyvanse) will be preferred on the BCBSND Formulary and Health Insurance Marketplace (HIM) formulary. Brand name Vyvanse will be a non-formulary/non-preferred medication on these formularies starting Jan. 1, 2026.
Current Vyvanse utilizers on the Blue Cross Blue Shield of North Dakota (BCBSND) or HIM formularies will be allowed to continue filling Vyvanse at the formulary rate until March 31, 2026. As this is a brand-to-generic change, new prescriptions should not be needed at the pharmacy.
This formulary update does not impact the NetResults formulary as Lisdexamfetamine is already the formulary agent and Vyvanse is non-formulary.